PD-1 blockade induces responses by inhibiting adaptive immune resistance
University of California, Los Angeles · Merck & Co., Inc., Rahway, NJ, USA (United States) · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
6,605
total citations
- FWCI
- 203.91
- Percentile
- 100%
- References
- 25
Citations per year
Authors
26- PCPaul C. TumehCorresponding
University of California, Los Angeles
- CLChristina L. Harview
University of California, Los Angeles
- JHJennifer H. Yearley
Merck & Co., Inc., Rahway, NJ, USA (United States)
- IPI. Peter Shintaku
University of California, Los Angeles
- ETEmma Taylor
University of California, Los Angeles
Topics & keywords
Topics
Keywords
- Immune system
- PD-L1
- CD8
- Blockade
- Antigen
- Cancer research
- Pembrolizumab
- Immune checkpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAAmerican Association for Cancer Research
- CRCancer Research InstituteAwards: SU2C-AACR-DT1012, CA16042
- MRMelanoma Research AllianceAward: SU2C-AACR-DT1012
- ABAdaptive Biotechnologies
- IGInstitut Gustave-Roussy
- SESociedad Española de Oncología Médica
- NINational Institutes of HealthAwards: P30 CA16042, CA16042, R01 CA170689, UL1TR000124, P01 CA168585, SU2C-AACR-DT1012
- SUStand Up To CancerAward: SU2C-AACR-DT1012